发明名称 ANTI-TNF- / ANTI-IL-23 BISPECIFIC ANTIBODIES
摘要 Bispecific antibodies are provided that bind Tumor Necrosis Factor alpha (TNFα) and the p19 subunit of Interleukin-23 (IL-23p19) and are characterized as having high affinity and strong simultaneous neutralizing properties to both TNFα and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Axial Spondyloarthropathy, Rheumatoid Arthritis and Psoriatic Arthritis.
申请公布号 US2016122429(A1) 申请公布日期 2016.05.05
申请号 US201514930678 申请日期 2015.11.03
申请人 Eli Lilly and Company 发明人 Millican Rohn L;Seo Neungseon;Na Songqing;Beidler Catherine B.
分类号 C07K16/24 主分类号 C07K16/24
代理机构 代理人
主权项 1. A bispecific antibody comprising an immunoglobulin G antibody (IgG) that binds tumor necrosis factor alpha (TNFα) conjugated to two single chain variable fragments (scFv) that bind the p19 subunit of IL-23 (IL23p19) wherein, a.) said IgG comprises two heavy chains (HC) and two light chains (LC), each HC comprises a heavy chain variable region (HCVR1) comprising heavy chain CDRs (HCDR) 1-3 and each LC comprises a light chain variable region (LCVR1) comprising light chain CDRs (LCDR) 1-3, wherein the amino acid sequence of HCDR1 is SEQ ID NO:9, the amino acid sequence of HCDR2 is SEQ ID NO:10, the amino acid sequence of HCDR3 is SEQ ID NO:11, the amino acid sequence of LCDR1 is SEQ ID NO:15, the amino acid sequence of LCDR2 is SEQ ID NO:16, and the amino acid sequence of LCDR3 is SEQ ID NO:17; and b.) each scFv comprises a heavy chain variable region (HCVR2) and a light chain variable region (LCVR2), the HCVR2 comprising HCDRs 4-6 and the LCVR2 comprising LCDRs 4-6, wherein the amino acid sequence of HCDR4 is SEQ ID NO:12, the amino acid sequence of HCDR5 is SEQ ID NO:13, the amino acid sequence of HCDR6 is SEQ ID NO:14, the amino acid sequence of LCDR4 is SEQ ID NO:18, the amino acid sequence of LCDR5 is SEQ ID NO:19, and the amino acid sequence of LCDR6 is SEQ ID NO:20,wherein each scFv is independently conjugated to said IgG antibody via a polypeptide linker (L1) covalently attached to the C-terminus of each IgG HC and the N-terminus of HCVR2 of each scFv, and the HCVR2 of each scFv is covalently attached to the LCVR2 of the same scFv via a second polypeptide linker (L2) covalently attached to the C-terminus of the HCVR2 and the N-terminus of the LCVR2 of the same scFv.
地址 Indianapolis IN US
您可能感兴趣的专利